ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation : The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC).

/pdf/2015-esc-guidelines-for-the-management-of-acute-coronary-6did6h5nxk.pdf

2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC)

2018 ESC/EACTS Guidelines on myocardial revascularization.

Authors/Task Force Members: Franz-Josef Neumann* (ESC Chairperson) (Germany), Miguel Sousa-Uva* (EACTS Chairperson) (Portugal), Anders Ahlsson (Sweden), Fernando Alfonso (Spain), Adrian P. Banning (UK), Umberto Benedetto (UK), Robert A. Byrne (Germany), Jean-Philippe Collet (France), Volkmar Falk (Germany), Stuart J. Head (The Netherlands), Peter Jüni (Canada), Adnan Kastrati (Germany), Akos Koller (Hungary), Steen D. Kristensen (Denmark), Josef Niebauer (Austria), Dimitrios J. Richter (Greece), Petar M. Seferovi c (Serbia), Dirk Sibbing (Germany), Giulio G. Stefanini (Italy), Stephan Windecker (Switzerland), Rashmi Yadav (UK), Michael O. Zembala (Poland) Document Reviewers: William Wijns (ESC Review Co-ordinator) (Ireland), David Glineur (EACTS Review Co-ordinator) (Canada), Victor Aboyans (France), Stephan Achenbach (Germany), Stefan Agewall (Norway), Felicita Andreotti (Italy), Emanuele Barbato (Italy), Andreas Baumbach (UK), James Brophy (Canada), Héctor Bueno (Spain), Patrick A. Calvert (UK), Davide Capodanno (Italy), Piroze M. Davierwala

/pdf/2014-esc-eacts-guidelines-on-myocardial-revascularization-3fr5n9jz36.pdf

2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI).

Atherosclerotic cardiovascular disease results in >19 million deaths annually, and coronary heart disease accounts for the majority of this toll. Despite major advances in treatment of coronary heart disease patients, a large number of victims of the disease who are apparently healthy die suddenly without prior symptoms. Available screening and diagnostic methods are insufficient to identify the victims before the event occurs. The recognition of the role of the vulnerable plaque has opened new avenues of opportunity in the field of cardiovascular medicine. This consensus document concludes the following. (1) Rupture-prone plaques are not the only vulnerable plaques. All types of atherosclerotic plaques with high likelihood of thrombotic complications and rapid progression should be considered as vulnerable plaques. We propose a classification for clinical as well as pathological evaluation of vulnerable plaques. (2) Vulnerable plaques are not the only culprit factors for the development of acute coronary syndromes, myocardial infarction, and sudden cardiac death. Vulnerable blood (prone to thrombosis) and vulnerable myocardium (prone to fatal arrhythmia) play an important role in the outcome. Therefore, the term "vulnerable patient" may be more appropriate and is proposed now for the identification of subjects with high likelihood of developing cardiac events in the near future. (3) A quantitative method for cumulative risk assessment of vulnerable patients needs to be developed that may include variables based on plaque, blood, and myocardial vulnerability. In Part I of this consensus document, we cover the new definition of vulnerable plaque and its relationship with vulnerable patients. Part II of this consensus document focuses on vulnerable blood and vulnerable myocardium and provide an outline of overall risk assessment of vulnerable patients. Parts I and II are meant to provide a general consensus and overviews the new field of vulnerable patient. Recently developed assays (eg, C-reactive protein), imaging techniques (eg, CT and MRI), noninvasive electrophysiological tests (for vulnerable myocardium), and emerging catheters (to localize and characterize vulnerable plaque) in combination with future genomic and proteomic techniques will guide us in the search for vulnerable patients. It will also lead to the development and deployment of new therapies and ultimately to reduce the incidence of acute coronary syndromes and sudden cardiac death. We encourage healthcare policy makers to promote translational research for screening and treatment of vulnerable patients.

/pdf/from-vulnerable-plaque-to-vulnerable-patient-a-call-for-new-47rrnyxj2m.pdf

From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II.

Gold nanoparticles have been used in biomedical applications since their first colloidal syntheses more than three centuries ago. However, over the past two decades, their beautiful colors and unique electronic properties have also attracted tremendous attention due to their historical applications in art and ancient medicine and current applications in enhanced optoelectronics and photovoltaics. In spite of their modest alchemical beginnings, gold nanoparticles exhibit physical properties that are truly different from both small molecules and bulk materials, as well as from other nanoscale particles. Their unique combination of properties is just beginning to be fully realized in range of medical diagnostic and therapeutic applications. This critical review will provide insights into the design, synthesis, functionalization, and applications of these artificial molecules in biomedicine and discuss their tailored interactions with biological systems to achieve improved patient health. Further, we provide a survey of the rapidly expanding body of literature on this topic and argue that gold nanotechnology-enabled biomedicine is not simply an act of ‘gilding the (nanomedicinal) lily’, but that a new ‘Golden Age’ of biomedical nanotechnology is truly upon us. Moving forward, the most challenging nanoscience ahead of us will be to find new chemical and physical methods of functionalizing gold nanoparticles with compounds that can promote efficient binding, clearance, and biocompatibility and to assess their safety to other biological systems and their long-term term effects on human health and reproduction (472 references).

The golden age: gold nanoparticles for biomedicine

We present a framework for high-performance deep learning despeckling based on a conditional generative adversarial network that can be trained and implemented easily in a multitude of OCT systems.

Plug-and-Play Deep Learning Framework for Volumetric Speckle Reduction in OCT

Summary form only given Recent advances in molecular biology techniques have permitted the site specific insertion of predetermined mutations into embryos for the investigation of normal and abnormal development Currently, there are several imaging modalities available to observe the expression of genetic mutations, but these typically require small, transparent, or fixed specimens Optical coherence tomography (OCT) offers the ability to image in vivo developing morphology in many of the animal models used for genetic studies In addition, OCT has the potential to rapidly and repeatedly acquire optical histology to assess development and to identify the expression of normal and abnormal genes Optical coherence tomography is an imaging modality that permits the in vivo investigation of biological specimens on the micron scale The imaging technique can be thought of as an analog to ultrasound B-mode imaging except backscattering of light from biological tissue layers is detected rather than acoustic reflections OCT incorporates a fiber-optic-based Michelson interferometer using a 1300-nm low-coherent superluminescent diode (SLD) as its light source to measure the intensity of optical backscattering from within the specimen OCT images are shown of in vivo developing morphology from a leopard frog tadpole

Optical coherence tomography of developing embryonic morphology

In this study, we demonstrate a 12x36 mm motorized capsule for OCT imaging of the esophagus. The capsule produces unobstructed images by using a distal reflector design, thus avoiding shadow caused by the motor wires. The motor synchronous control enables three working modes: circumferential imaging, angular sector imaging and accurate beam positioning. Distortion artifacts shown in the sector imaging were found to be induced by velocity changes of the motor. We specifically characterized the motor speed and found a symmetric and repeatable behavior during sector scanning. Resampling of the sector images A-lines was carried out to achieve uniform angular spacing according to the measured speed profile. Also, distortion between consecutive sector frames was corrected using image registration to achieve stable imaging.

/pdf/shadow-free-motorized-capsule-enables-accurate-beam-20cjdi169s.pdf

Brett E. Bouma

Papers

Plug-and-Play Deep Learning Framework for Volumetric Speckle Reduction in OCT

Optical coherence tomography of developing embryonic morphology

Shadow-free motorized capsule enables accurate beam positioning and sectorized OCT imaging of the esophagus

Abstract 3431: Comparison of Coronary Plaque Characteristics Between Diabetic and Non-Diabetic Subjects: An in-vivo Optical Coherence Tomography Study

Two and three dimensional imaging of normal and osteoarthritic cartilage microstructure with optical coherence tomography